Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd..
An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium-glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log10 -transformed urinary N-acetyl-β-D-glucosaminidase ratio were significantly correlated with the reduction in serum UA levels at both 4 and 24 weeks in multivariate analysis (respectively, P < .0001). The decrease in HbA1c levels was greatest in the group with the highest baseline HbA1c level (quartile 4; HbA1c > 8.6%) and lowest in the group with the lowest baseline HbA1c level (quartile 1; HbA1c ≤ 7.4%). The decrease in serum UA levels was greatest in the quartile 1 group and lowest in the quartile 4 group. In most groups, the maximum decrease in serum UA levels was seen in the first 4 weeks, while the maximum decrease in HbA1c was seen at week 24. Thus, serum UA levels were significantly decreased in patients with moderate HbA1c levels.
| Errataetall: |
CommentIn: Diabetes Obes Metab. 2018 Aug;20(8):2039-2040. - PMID 29660244 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Diabetes, obesity & metabolism - 20(2018), 4 vom: 08. Apr., Seite 1061-1065 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ouchi, Motoshi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.01.2019 Date Revised 07.12.2022 published: Print-Electronic CommentIn: Diabetes Obes Metab. 2018 Aug;20(8):2039-2040. - PMID 29660244 Citation Status MEDLINE |
|---|
| doi: |
10.1111/dom.13170 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM278378420 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM278378420 | ||
| 003 | DE-627 | ||
| 005 | 20231225020432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.13170 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0927.xml |
| 035 | |a (DE-627)NLM278378420 | ||
| 035 | |a (NLM)29171930 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ouchi, Motoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2019 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Diabetes Obes Metab. 2018 Aug;20(8):2039-2040. - PMID 29660244 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. | ||
| 520 | |a An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium-glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log10 -transformed urinary N-acetyl-β-D-glucosaminidase ratio were significantly correlated with the reduction in serum UA levels at both 4 and 24 weeks in multivariate analysis (respectively, P < .0001). The decrease in HbA1c levels was greatest in the group with the highest baseline HbA1c level (quartile 4; HbA1c > 8.6%) and lowest in the group with the lowest baseline HbA1c level (quartile 1; HbA1c ≤ 7.4%). The decrease in serum UA levels was greatest in the quartile 1 group and lowest in the quartile 4 group. In most groups, the maximum decrease in serum UA levels was seen in the first 4 weeks, while the maximum decrease in HbA1c was seen at week 24. Thus, serum UA levels were significantly decreased in patients with moderate HbA1c levels | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a sodium-glucose cotransporter 2 inhibitor | |
| 650 | 4 | |a tofogliflozin | |
| 650 | 4 | |a uric acid | |
| 650 | 4 | |a urinary N-acetyl-β-D-glucosaminidase | |
| 650 | 7 | |a Benzhydryl Compounds |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Glucosides |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Uric Acid |2 NLM | |
| 650 | 7 | |a 268B43MJ25 |2 NLM | |
| 650 | 7 | |a 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol |2 NLM | |
| 650 | 7 | |a P8DD8KX4O4 |2 NLM | |
| 700 | 1 | |a Oba, Kenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Kaku, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Suganami, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Akihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fukunaka, Yasunori |e verfasserin |4 aut | |
| 700 | 1 | |a Jutabha, Promsuk |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Asuka |e verfasserin |4 aut | |
| 700 | 1 | |a Otani, Naoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Keitaro |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Tomoe |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Yasutake, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Anzai, Naohiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 20(2018), 4 vom: 08. Apr., Seite 1061-1065 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2018 |g number:4 |g day:08 |g month:04 |g pages:1061-1065 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.13170 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2018 |e 4 |b 08 |c 04 |h 1061-1065 | ||